<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05032937</url>
  </required_header>
  <id_info>
    <org_study_id>012</org_study_id>
    <nct_id>NCT05032937</nct_id>
  </id_info>
  <brief_title>the Accuracy and Safety of Coronary Artery Contrast-enhanced Magnetic Resonance Imaging With Polysaccharide Superparamagnetic Iron Oxide Nanoparticle</brief_title>
  <official_title>Clinical Study of Domestic Polysaccharide Superparamagnetic Iron Oxide Nanoparticle Injection for Coronary Artery Contrast-enhanced Magnetic Resonance Contrast-enhanced Angiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>School of Bioscience &amp; Medical Engineering, Southeast University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>School of Biomedical Engineering &amp; Informatics, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, prospective, controlled and diagnostic clinical trial which will&#xD;
      enroll 30 patients scheduled for coronary angiography in China.Patients will receive&#xD;
      contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide&#xD;
      nanoparticle before percutaneous coronary angiography.In order to evaluate the safety of&#xD;
      polysaccharide superparamagnetic iron oxide nanoparticle, patients will detect iron levels in&#xD;
      peripheral and tissue before and after the examination.The main indicators of the study are&#xD;
      the degree of coronary artery stenosis and the stability of coronary atherosclerotic plaque&#xD;
      assessed by contrast-enhanced cardiac magnetic resonance with polysaccharide&#xD;
      superparamagnetic iron oxide nanoparticle.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The degree of coronary artery stenosis</measure>
    <time_frame>baseline</time_frame>
    <description>Degree of coronary artery stenosis assessed by contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The degree of coronary artery stenosis</measure>
    <time_frame>72 hours</time_frame>
    <description>Degree of coronary artery stenosis assessed by quantitative coronary angiography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plaque stability of coronary atherosclerotic plaques</measure>
    <time_frame>baseline</time_frame>
    <description>Plaque stability of coronary atherosclerotic plaques assessed by contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plaque stability of coronary atherosclerotic plaques</measure>
    <time_frame>72 hours</time_frame>
    <description>Plaque stability of coronary atherosclerotic plaques assessed by Optical coherence tomography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood routine</measure>
    <time_frame>baseline,72 hours,30 Days,3 months</time_frame>
    <description>Blood routine examination of patients before and after examination to evaluate general condition of patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood biochemistry</measure>
    <time_frame>baseline,72 hours,30 Days,3 months</time_frame>
    <description>Blood biochemistry examination of patients before and after examination to evaluate liver function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine routine</measure>
    <time_frame>baseline,72 hours,30 Days,3 months</time_frame>
    <description>Urine routine examination of patients before and after examination to evaluate kidney function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24-hour urine biochemistry</measure>
    <time_frame>baseline,72 hours,30 Days,3 months</time_frame>
    <description>24-hour urine biochemistry examination of patients before and after examination to evaluate kidney function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinol binding protein</measure>
    <time_frame>baseline,72 hours,30 Days,3 months</time_frame>
    <description>Retinol binding protein examination of patients before and after examination to evaluate kidney function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutrophil gelatinase-associated lipocalin</measure>
    <time_frame>baseline,72 hours,30 Days,3 months</time_frame>
    <description>Neutrophil gelatinase-associated lipocalin examination of patients before and after examination to evaluate kidney function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum iron</measure>
    <time_frame>baseline,72 hours,30 Days,3 months</time_frame>
    <description>Determination of serum iron before and after ECMR to evaluate the changes of iron content in peripheral blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ferritin</measure>
    <time_frame>baseline,72 hours,30 Days,3 months</time_frame>
    <description>Determination of serum ferritin before and after ECMR to evaluate the changes of iron content in peripheral blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transferrin</measure>
    <time_frame>baseline,72 hours,30 Days,3 months</time_frame>
    <description>Determination of serum transferrin before and after ECMR to evaluate the changes of iron content in peripheral blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of iron content in tissues between different time points</measure>
    <time_frame>baseline,6 months</time_frame>
    <description>Evaluation of tissue iron content by T1W MRI before and after ECMR.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">11</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>ECMR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>domestic polysaccharide superparamagnetic iron oxide nanoparticle</intervention_name>
    <description>Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.</description>
    <arm_group_label>ECMR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰§ 18 years, &lt; 65 years;&#xD;
&#xD;
          -  Patients who planned coronary angiography ;&#xD;
&#xD;
          -  Patients with normal renal function or CKD stage 1-3;&#xD;
&#xD;
          -  Patients themselves or authorized families to sign informed consent voluntarily.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who were allergic to iodine contrast agent or had allergic history or&#xD;
             allergic constitution to iron and dextran;&#xD;
&#xD;
          -  Patients who can ' t accept magnetic resonance examination because of psychological (&#xD;
             such as autism syndrome ) or physical reasons ( such as metal retention in the body );&#xD;
&#xD;
          -  Malignancies or other comorbid conditions with life expectancy less than 1 year;&#xD;
&#xD;
          -  Pregnant or lactating woman;&#xD;
&#xD;
          -  Hearing impaired persons;&#xD;
&#xD;
          -  Cardiac function grade III-IV;&#xD;
&#xD;
          -  History of coronary stenting or coronary artery bypass grafting;&#xD;
&#xD;
          -  Patients who were taking other iron agents orally or intravenously;&#xD;
&#xD;
          -  Patients with hemosiderin deposition or hemochromatosis;&#xD;
&#xD;
          -  Patients with acute coronary syndromes;&#xD;
&#xD;
          -  Any other patients that researcher deems it's unsuitable to be admitted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunjian Li, Dr, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunjian Li, Dr, PhD</last_name>
    <phone>+86-13701465229</phone>
    <email>drcjli@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhou Dong</last_name>
    <phone>+86-15555369180</phone>
    <email>dongzhou1997@yeah.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fuming Zhang, M.D.</last_name>
      <phone>+86-25-83718836</phone>
      <phone_ext>6360</phone_ext>
      <email>jsphkj@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yi Chai, M.D.</last_name>
      <phone>+86-25-83718836</phone>
      <phone_ext>6360</phone_ext>
      <email>jsphkj@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 21, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Chunjian Li</investigator_full_name>
    <investigator_title>Dr., MD, Ph.D, Director of CCU Ward</investigator_title>
  </responsible_party>
  <keyword>Ultrasmall Superparamagnetic Particles of Iron Oxide</keyword>
  <keyword>Contrast-Enhanced Magnetic Resonance</keyword>
  <keyword>Plaque Stability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

